Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer
Status:
Terminated
Trial end date:
2021-08-03
Target enrollment:
Participant gender:
Summary
The main objective of the trial is to determine the efficacy of doxorubicin-loaded anti-EGFR
immunoliposomes as first-line therapy in patients with advanced triple Negative, EGFR
positive breast cancer. In this proof of concept trial, all patients will have an
administration of the doxorubicin-loaded anti-EGFR immunoliposomes (anti-EGFR-IL-dox) every
28 days, until progression or unacceptable toxicity.